Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercise and Stock Sale

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on October 18, 2024, according to a recent SEC filing.

Summary

• On October 18, 2024, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, exercised options to purchase 814 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 814 shares of common stock at a weighted average price of $30.003, with individual sales ranging from $30.00 to $30.03.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 0 shares of Enliven Therapeutics.
• The options were originally for 262,120 shares, vesting over time.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions by an officer, which is a routine occurrence. There is no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders can monitor insider transactions for insights into management's perspective on the company's value.

Key Dates